Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 183 publications
Author Correction: The dynamic spectrum of steatotic liver disease: the global perspective.
Journal: Nature reviews. Gastroenterology & hepatology
Published: August 14, 2026
The dynamic spectrum of steatotic liver disease: the global perspective.
Journal: Nature reviews. Gastroenterology & hepatology
Published: July 10, 2026
The dynamic spectrum of steatotic liver disease: the global perspective.
Journal: Nature reviews. Gastroenterology & hepatology
Published: July 10, 2026
The economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: June 30, 2026
Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics.
Journal: Alimentary pharmacology & therapeutics
Published: April 15, 2026
Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management.
Journal: Nature reviews. Gastroenterology & hepatology
Published: February 24, 2026
The Transitional Liver Clinic: Study protocol for a stepped-wedge cluster randomized trial.
Journal: Hepatology communications
Published: February 22, 2026
Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis.
Journal: Med (New York, N.Y.)
Published: January 12, 2026
MASLD as a complication of obesity must include liver risk stratification.
Journal: Nature medicine
Published: January 07, 2026
Response to "Aspirin for Primary Prevention in Metabolic Dysfunction-Associated Steatotic Liver Disease".
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: December 26, 2025
Accuracy of the FIB-4 and LiverRisk score for use in primary risk assessment for liver fibrosis, and variation by age.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: December 03, 2025
Refining HEPAmet for Treatment Eligibility in Metabolic Dysfunction-Associated Steatotic Liver Disease: External Validation and Guardrail to Exclude Cirrhosis, Limit Early Disease.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: November 23, 2025
Last Updated: 09/26/2026